Save this technology
close
Save to Existing Project
Save to a New Project
Phase I/II Drug for PHN
Cosmederm Bioscience Inc. United States flag United States
Abstract ID:
Cosmederm Bioscience has developed a family of small molecule compounds for topical treatment of inflammatory dermatological conditions and nerve pain
Contact Ramin Eghbali
RE:
Participants
You

Cosmederm Bioscience has a patented family of anti-itch, anti-inflammatory and anti-irritant small molecule compounds that can selectively suppress the symptoms of stinging, burning and itching and associated neurogenic inflammation in both keratinized skin and mucous membranes.

The technology is a potent anti-itch agent, and is a powerful inhibitor of inflammatory cytokines and neuropeptides such as TNF-α, IL-1α and IL-6.

The lead drug candidate, C746, is currently in a phase I/II trial with a targeted indication of PHN and or diabetic neuropathy.

A second candidate, C745, is preclinical and being developed for atopic dermatitis and/or general pruritus.

GO PREMIUM TO GET PATENT INFORMATION
Type of Business Relationship Sought
Licensing, joint development
FEATURED
Last Updated Nov 2014
Technology Type THERAPEUTIC
Phase of Development REGISTERED / FINISHED PRODUCT
CORPORATION

Opportunity Contact